Loading clinical trials...
Loading clinical trials...
An Open-label, Multicentre, Phase II Study to Evaluate the Safety and Efficacy of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Conditions
Interventions
Irinotecan Liposome Injection
SG001
+2 more
Locations
1
China
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Hangzhou, Zhejiang, China
Start Date
September 1, 2021
Primary Completion Date
January 16, 2023
Completion Date
January 16, 2023
Last Updated
July 11, 2024
NCT04891289
NCT07282912
NCT06313203
NCT07337850
NCT06440993
NCT06925516
Lead Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions